Association between Inhaled β-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study.

Purpose: Despite ample evidence underpinning the efficacy of β-agonists in asthma and chronic obstructive pulmonary disease (COPD), the occurrence of β- and β-adrenoceptors in the heart suggests that β-agonists may have deleterious cardiac effects. We investigated the association between new users of long-or short-acting β-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA and major adverse cardiovascular events (MACE).

Methods: A nested case-control analysis was conducted using the UK Clinical Practice Research Datalink of patients with asthma, COPD or asthma-COPD overlap with initial treatment of LABA, SABA, ICS/LABA, ICS, long-or short-acting muscarinic antagonist (LAMA or SAMA) between 01 January 1998 and 31 July 2018. The primary outcome was MACE, defined as the first occurrence of stroke, heart failure, myocardial infarction, arrhythmia, or cardiovascular death. Each case was matched with up to 10 controls on age, sex, date of cohort-entry, and duration of follow-up. The risk of MACE associated with β-agonists was estimated using conditional logistic regression after controlling for potential confounders.

Results: The cohort included 180,567 new users of β-agonists, ICS, SAMA, or LAMA. Among asthmatics, β-agonists were not associated with the risk of MACE (SABA vs ICS: HR 1.29 [0.96-1.73]; ICS/LABA vs ICS, HR 0.75 [0.33-1.73]). In contrast, among COPD patients, LABA (HR, 2.38 [1.04-5.47]), SABA (HR, 2.02 [1.13-3.59]) and ICS/LABA (HR, 2.08 [1.04-4.16]) users had an increased risk of MACE compared with SAMA users. Among patients with asthma-COPD overlap, SABA (HR, 2.57 [1.26-5.24]) was associated with an increased risk of MACE compared with ICS.

Conclusion: In conclusion, initiation of LABA, SABA, or ICS/LABA in COPD or SABA in asthma-COPD overlap is associated with increased risk of MACE. No associations were observed among patients with asthma.